Mitiglinide is a Small Molecule owned by Kissei Pharmaceutical, and is involved in 10 clinical trials, which were completed.

Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive potassium channels in pancreatic beta-cells. The closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.

The revenue for Mitiglinide is expected to reach a total of $42m through 2031. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mitiglinide NPV Report.

Mitiglinide is originated and owned by Kissei Pharmaceutical.

Mitiglinide Overview

Mitiglinide calcium (Glufast) is a phenylpropanoic acid derivative, acts as an insulin secretagogue or anti-diabetic agent. It is formulated as tablets for oral route of administration. Glufast is indicated for treatment of type 2 diabetes and for post prandial glycemic control in type 2 diabetes mellitus.

It was under development for type 2 diabetes mellitus in Vietnam (ASEAN country)

Kissei Pharmaceutical Overview

Kissei Pharmaceutical (Kissei) discovers, develops, manufactures, and sells a range of innovative pharmaceutical products. The company’s pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drugs for obstetrics and gynecology, ophthalmic medicine and rare disease medicine. It also develops and sells health foods including protein-controlled food, energy supply food, calorie-controlled food, and elderly controlled food. Kissei conducts research to develop novel drugs and improve existing drugs and provide superior drugs to people worldwide. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto, Japan.

The company reported revenues of (Yen) JPY65,381 million for the fiscal year ended March 2022 (FY2022), a decrease of 5.3% over FY2021. The operating loss of the company was JPY1,842 million in FY2022, compared to an operating profit of JPY2,151 million in FY2021. In FY2022, the company recorded a net margin of 19.8%, compared to a net margin of 7.7% in FY2021. The company reported revenues of JPY16,579 million for the second quarter ended September 2022, an increase of 1.8% over the previous quarter.

Quick View – Mitiglinide

Report Segments
  • Innovator (NME)
Drug Name
  • Mitiglinide
Administration Pathway
  • Oral
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.